The North America lab consumables market demonstrated consistent revenue growth from 2020 to 2025, reaching $5,600 million in the base year 2025. Forecasts project steady expansion through 2035 driven by sustained demand in pharmaceutical, biotech, and clinical research arenas. The chart displays a positive upward trend, reflective of continuous scientific advancements, increased funding for research, and the integration of automation in laboratory environments. The market’s resilient growth trajectory highlights the indispensable role of consumables across all laboratory functions.

Read More - https://bussinessinsights.com/research-report/north-america-lab-consumables-market

Research applications represent the largest use case for lab consumables in North America, primarily driven by ongoing investments from academic institutes and private R&D organizations. Diagnostics follow, spurred by high-volume clinical testing and advancements in molecular diagnostics, especially post-pandemic. Quality control and drug development continue to contribute significantly to demand, as regulatory standards tighten and pharmaceutical pipelines grow. Academic usage remains resilient, reflecting steady funding and innovation across university research labs. The mature application landscape reinforces the importance of consumables in both routine and cutting-edge scientific endeavors.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-lab-consumables-market

Frequently Asked Questions

Who are the key players in North America Lab Consumables Market industry?
The top five players are Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Corning Inc., and VWR International. These companies dominate through extensive product portfolios, innovative solutions, strong distribution networks, and strategic acquisitions, helping them set industry standards and serve a broad range of laboratory and research needs across North America.

What is the North America Lab Consumables Market growth?
The North America Lab Consumables Market has exhibited robust growth, driven by the increasing demand for research and diagnostics post-pandemic. For example, Thermo Fisher Scientific reported significant revenue growth in 2023, attributing it to rising consumables sales in medical and life sciences research laboratories.

Which segment accounted for the largest North America Lab Consumables Market share?
The research and academic laboratories segment held the largest market share, fueled by expanding investments in life science and biomedical research. Institutions are increasing their purchase of core consumables, like pipettes, test tubes, and cell culture media, to support diverse experiments and innovative projects throughout North America.

Thanks & Regards,
priya
sales@bussinessinsights.com

The North America Point of Care Molecular Diagnostics Market is projected to reach a revenue of 4,100 Million USD in 2025, up from 2,100 Million USD in 2020. The market is forecast to grow steadily, culminating at approximately 9,300 Million USD by 2035, reflecting a CAGR of about 8.2% during the forecast period. This robust trajectory is powered by rapid adoption of innovative POCT technologies across healthcare settings, ongoing investments in R&D, and the continuous need for decentralized diagnostic solutions to manage public health threats.

Read More - https://bussinessinsights.com/research-report/north-america-point-of-care-molecular-diagnostics-market

In 2025, Infectious Diseases continue to drive the majority share in Point of Care Molecular Diagnostics applications, accounting for 46% of the segment due to the persistent threat of viral outbreaks and increasing attention to antimicrobial resistance. Oncology represents 17%, buoyed by innovations in rapid tumor marker detection, while Prenatal Testing holds a noteworthy 13% market share. The ease and speed of point-of-care solutions make them increasingly relevant for Hematology and Endocrinology, though these remain secondary to the leading segments. The diverse clinical utility of POCT amplifies its role in delivering timely and accurate diagnostic information across multiple care settings.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-point-of-care-molecular-diagnostics-market

Frequently Asked Questions

Who are the key players in North America Point of Care Molecular Diagnostics Market industry?
The top five players in the North America Point of Care Molecular Diagnostics Market are Abbott Laboratories, Roche Diagnostics, Cepheid (Danaher Corporation), BioMérieux SA, and Hologic Inc. These companies lead the market due to their innovative diagnostic platforms, strong product portfolios, and expanding distribution networks across the region.

What is the North America Point of Care Molecular Diagnostics Market growth?
The North America Point of Care Molecular Diagnostics Market is experiencing robust growth, propelled by rising demand for rapid infectious disease testing. Abbott Laboratories reported a surge in molecular testing revenues due to accelerated adoption during the COVID-19 pandemic, underscoring a sustained positive outlook for the sector.

Which segment accounted for the largest North America Point of Care Molecular Diagnostics Market share?
The infectious diseases segment holds the largest share in the North America Point of Care Molecular Diagnostics Market. This dominance is attributed to the high prevalence of diseases like influenza, RSV, and HIV, and the growing preference for rapid, accurate tests in clinical and outpatient settings.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America breast biopsy devices market revenue demonstrates a steady upward trend from 2020 (USD 597 million) to an estimated USD 1,250 million by 2035. Revenue growth is propelled by high disease prevalence, ongoing technology upgrades, and expanded insurance coverage for screening and diagnostic procedures. The CAGR over this period remains robust as hospitals, diagnostic centers, and ambulatory clinics continue integrating advanced biopsy systems, contributing to substantial market expansion.

Read More - https://bussinessinsights.com/research-report/north-america-breast-biopsy-devices-market

Early Cancer Detection accounts for the highest application segment in the breast biopsy devices market in North America for 2025. Tumor Identification and Routine Screening collectively drive more than half of total procedure volumes as population-wide screening programs expand. Genetics Study and Research Applications are on an upward trajectory with the advancement of personalized medicine and genomic research. The market’s focus remains solidly on improving clinical outcomes through early intervention.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-breast-biopsy-devices-market

Frequently Asked Questions

Who are the key players in North America Breast Biopsy Devices Market industry?
The key players in the North America Breast Biopsy Devices Market include Hologic, Inc., Becton Dickinson and Company (BD), Devicor Medical Products (a division of Leica Biosystems), Argon Medical Devices, and Stryker Corporation. These companies are renowned for their broad product portfolios, technological innovations, and strategic market presence.

What is the North America Breast Biopsy Devices Market growth?
The North America Breast Biopsy Devices Market is experiencing steady growth, driven by increased breast cancer screening initiatives and advanced product launches. For example, in 2023, Hologic, Inc. introduced next-generation biopsy systems, enhancing market adoption and contributing to projected annual growth rates above 7%.

Which segment accounted for the largest North America Breast Biopsy Devices Market share?
The diagnostic segment holds the largest market share in the North America Breast Biopsy Devices Market. The rising prevalence of breast cancer, coupled with significant utilization of minimally invasive diagnostic procedures, has resulted in strong demand for breast biopsy devices across hospitals and diagnostic centers.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America Cell Expansion Market is witnessing a steady increase in revenue, rising from USD 1,420 Million in 2020 to an expected USD 2,350 Million in 2025. Strong investments, technological advancements, and expanding applications in immunotherapy and regenerative medicine are the primary growth factors. Continued demand from clinical research organizations, biotechnology firms, and academic institutes is expected to propel market revenues further, surpassing USD 4,900 Million by 2035. This trajectory demonstrates sustained growth supported by a favorable policy environment, improved infrastructure, and a mature healthcare ecosystem.

Read More - https://bussinessinsights.com/research-report/north-america-cell-expansion-market

Regenerative Medicine & Stem Cell Research ranks as the leading application segment in 2025, highlighting the region’s dynamic research and clinical translation activities. Cancer & Cell-based Research is another key area, fueled by increased funding for oncology and the success of CAR-T therapy products. Clinical Diagnostics is gaining traction due to advances in personalized medicine and cell-based assays. Tissue Engineering, Drug Screening & Development, and other applications reflect a diversified market that leverages expanded cell lines to support life sciences innovation and next-generation therapies.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-cell-expansion-market

Frequently Asked Questions

Who are the key players in North America Cell Expansion Market industry?
The top 5 players in the North America Cell Expansion Market include Thermo Fisher Scientific, Merck KGaA, Lonza Group, Becton Dickinson and Company, and Corning Incorporated. These companies offer advanced cell expansion solutions and technologies, driving innovation and supporting applications in research, regenerative medicine, and biopharmaceutical production.

What is the North America Cell Expansion Market growth?
The North America Cell Expansion Market is experiencing robust growth, propelled by increased funding in cell-based research and technological advancements. In 2023, Thermo Fisher Scientific expanded its cell therapy services to address rising demand for regenerative medicine, reflecting a strong growth trajectory in the region.

Which segment accounted for the largest North America Cell Expansion Market share?
The regenerative medicine and stem cell research segment holds the largest market share in the North America Cell Expansion Market. This dominance is attributed to the rising adoption of cell therapies and increased focus on research and clinical applications for chronic diseases and cancer treatment.

Thanks & Regards,
Priya
sales@bussinessinsights.com

From 2020 to 2035, the North America Continuous Manufacturing Market is forecast to expand consistently, reflecting escalating interest in automation and efficiency across industries. In 2025, market revenue is projected at 4,800 Million USD, up from 2,900 Million USD in 2020, and is on track to surpass 11,200 Million USD by 2035. The jump in annual revenue correlates with investments in integrated manufacturing systems, advanced analytics, and regulatory support for digital transformation. Sustained growth is anticipated as new segments and applications emerge, broadening the region’s adoption of these technologies.

Read More - https://bussinessinsights.com/research-report/north-america-continuous-manufacturing-market

The pharmaceutical industry commands the majority of the continuous manufacturing market share in North America, benefiting from regulatory encouragement and a focus on consistent product quality. The chemical and food & beverage segments are robust, with process efficiency and higher throughput driving continuous adoption. Petrochemical and cosmetics applications are climbing, although to a lesser extent, while the 'Others' segment captures emerging uses such as specialty materials and nutraceuticals. This distribution underscores the sector’s established alignment with demanding, quality-centric industries that value scalability and flexibility.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-continuous-manufacturing-market

Frequently Asked Questions

Who are the key players in North America Continuous Manufacturing Market industry?
Key players include Thermo Fisher Scientific, GEA Group, Siemens AG, Bosch Packaging Technology, and Pfizer Inc. These organizations are renowned for advancing process automation, enhancing pharmaceutical production efficiency, and investing in R&D to provide innovative continuous manufacturing solutions throughout the North American pharmaceutical sector.

What is the North America Continuous Manufacturing Market growth?
The North America Continuous Manufacturing Market has witnessed robust growth, registering a CAGR of over 10% in recent years. Key drivers include Pfizer's investments in advanced manufacturing technologies, particularly for continuous production of oral solid dosage forms, to streamline and accelerate pharmaceutical manufacturing processes.

Which segment accounted for the largest North America Continuous Manufacturing Market share?
The pharmaceutical application segment holds the largest market share in North America Continuous Manufacturing Market. Increasing demand for efficient production of oral solid dosage forms, as well as regulatory support from the US FDA, have supported adoption among leading pharmaceutical companies for high-volume drug production.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America disposable medical device sensors market is projected to experience robust growth between 2020 and 2035. In 2025, the market is estimated at 4,800 Million, with strong development expected to push the value to 12,500 Million by 2035. This upward trend is driven by heightened adoption of patient monitoring and diagnostic applications, ongoing innovation among key manufacturers, and expanding distribution through online and retail channels. The year-on-year growth signals resilient demand despite regulatory and cost-related challenges, positioning North America at the forefront of disposable sensor innovation and market scalability.

Read More - https://bussinessinsights.com/research-report/north-america-disposable-medical-device-sensors-market

Patient monitoring will account for the largest share of disposable medical device sensors applications in North America for 2025, reflecting the pressing need for real-time, remote monitoring in both acute and chronic care settings. Diagnostics will follow, as rapid, point-of-care diagnostic tests and sensors become standard across clinics and home care scenarios. Therapeutic applications are gaining momentum, especially in minimally invasive and targeted treatments powered by disposable sensors. This distribution highlights healthcare providers’ strategic focus on early detection, preventive care, and improved patient management outcomes, amplifying demand across both hospitals and ambulatory service channels.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-disposable-medical-device-sensors-market

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North American gene editing market revenue shows consistent growth from 2020, with a marked acceleration post-2025, driven by successful commercialization of CRISPR-based therapies, greater adoption in agriculture, and expanding research budgets. By 2035, the market is expected to reach nearly 12,000 million USD, reflecting a strong compound annual growth rate and the transformative impact of gene editing across multiple sectors.

Read More - https://bussinessinsights.com/research-report/north-america-gene-editing-market

Biomedical applications dominate the North American gene editing market in 2025, driven by rapid advancements in gene therapy and precision medicine for rare and complex diseases. Agriculture remains the second largest segment, leveraging gene editing to develop resilient crops and livestock. Research activities also command a significant share, reflecting continual exploration in both academia and industry. Industrial uses and animal genetic engineering are emerging with rising demand for sustainable solutions.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-gene-editing-market

Frequently Asked Questions

Who are the key players in North America Gene Editing Market industry?
Key players in the North America Gene Editing Market include Thermo Fisher Scientific, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Sangamo Therapeutics. These companies are at the forefront of developing innovative gene-editing technologies and therapeutics, driving industry growth through advanced research, strategic partnerships, and new product introductions.

What is the North America Gene Editing Market growth?
The North America Gene Editing Market is experiencing robust growth, driven by increased R&D investments and regulatory approvals. For instance, in 2023, CRISPR Therapeutics achieved significant milestones with FDA approval for gene-edited therapies, accelerating market expansion and attracting further investments in the region.

Which segment accounted for the largest North America Gene Editing Market share?
The therapeutics application segment holds the largest market share in North America. This is due to the rising adoption of gene editing for treating genetic disorders, cancer, and rare diseases. Companies like Editas Medicine and Intellia Therapeutics lead advancements in clinical therapeutic applications, fueling segment dominance.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America Women’s Health Diagnostics market is poised for substantial expansion between 2020 and 2035. In 2025, the market value is estimated at $10,500 million, rising to $27,400 million in 2035. This robust growth is attributed to increasing investments in diagnostic infrastructure, new technology launches, and heightened public awareness surrounding women's health. The market exhibits a steady CAGR, propelled by ongoing research, favorable regulatory climates, and evolving consumer behavior. Gradual broadening of insurance coverage and the expansion of telehealth and home-based diagnostics are further accelerating revenue growth across North America.

Read More - https://bussinessinsights.com/research-report/north-america-women’s-health-diagnostics-market

Cancer diagnostics account for the largest share of applications in the North America women’s health diagnostics market in 2025, due to ongoing awareness campaigns and accessible screening programs, particularly for breast and cervical cancer. Pregnancy and fertility diagnostics continue to grow, fueled by demographic shifts and a higher average maternal age. Infectious disease diagnostics are critical as women remain disproportionately at risk for certain infections. Cardiovascular and osteoporosis screening represents a stable share but is expected to grow with the aging population.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-women’s-health-diagnostics-market

Frequently Asked Questions

Who are the key players in North America Women’s Health Diagnostics Market industry?
The top five players in the North America Women’s Health Diagnostics Market include Hologic Inc., Quest Diagnostics, Abbott Laboratories, Siemens Healthineers, and Roche Diagnostics. These companies have established strong portfolios in women's health, focusing on innovation, comprehensive testing solutions, and advanced diagnostic technologies to maintain their market leadership.

What is the North America Women’s Health Diagnostics Market growth?
The North America Women’s Health Diagnostics Market has shown steady growth, driven by technological advancements and increased awareness of women’s health issues. For example, in 2023, Hologic Inc. reported significant gains in breast health diagnostics, reporting continued expansion and investments in new screening technologies.

Which segment accounted for the largest North America Women’s Health Diagnostics Market share?
The breast cancer testing segment accounted for the largest share of the North America Women’s Health Diagnostics Market. This dominance is due to the high incidence of breast cancer and rising demand for early detection tests, with mammography and related technologies widely adopted in hospitals and diagnostic centers.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America NGS-based RNA-sequencing market is expected to exhibit steady revenue growth from 2020 through 2035, underpinned by rapid technology adoption, expanding clinical applications, and increasing R&D spending. In 2025, total market revenue is projected to reach approximately 1,350 Million USD, with a sustained annual growth rate driven by advancements in sequencing technologies, integration of automation, and higher throughput capabilities. The market is forecast to surpass 3,540 Million USD by 2035 as genetic and transcriptomic profiling become routine in both academic and clinical environments.

Read More - https://bussinessinsights.com/research-report/north-america-ngs-based-rna-sequencing-market

Diagnostics is poised to be the leading application for NGS-based RNA-sequencing in North America by 2025, as hospitals and clinical labs increasingly incorporate transcriptomic data into oncology and rare disease diagnosis. Closely behind, drug discovery is leveraging RNA-seq for target identification and safety assessments, while biomarker discovery continues to gain momentum with a surge in translational research programs. This broadening adoption across healthcare and pharmaceutical research is expected to drive continued growth and innovation throughout the forecast period.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-ngs-based-rna-sequencing-market

Frequently Asked Questions

Who are the key players in North America NGS-based RNA-sequencing Market industry?
The top 5 players are Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and PerkinElmer. These companies drive innovation through advanced sequencing platforms, sample preparation solutions, and comprehensive bioinformatics. Their extensive product portfolios, strong distribution networks, and continuous investments in R&D significantly influence the North American RNA-sequencing landscape.

What is the North America NGS-based RNA-sequencing Market growth?
The North America NGS-based RNA-sequencing market has experienced robust growth, primarily driven by rising R&D activities and adoption in clinical diagnostics. For example, Illumina reported double-digit revenue growth in 2023, fueled by expanding applications in transcriptomics, personalized medicine, and biomarker discovery among research and healthcare institutions.

Which segment accounted for the largest North America NGS-based RNA-sequencing Market share?
In 2023, the research and academic institutes segment held the largest market share, owing to increased government funding and large-scale genomic studies. These organizations utilize NGS-based RNA sequencing for basic research, disease characterization, and biomarker discovery, driving significant adoption across projects and collaborations.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The market is expected to grow from $102,500 million in 2021 to $165,000 million in 2035, reflecting sustained expansion in technological adoption, chronic disease management, and supportive regulatory reforms. Annual revenue increases are particularly noticeable from 2025 onwards, as digital health and remote patient monitoring solutions consolidate their foothold in the market, aided by continued venture capital and public funding. Major players are anticipated to deepen their market penetration via mergers and acquisitions throughout this period. The trajectory demonstrates the North American region's leadership in medical device innovation and commercialization.

Read More - https://bussinessinsights.com/research-report/north-america-medical-device-technologies-market

In 2025, diagnostics lead the North America Medical Device Technologies Market with a 35% share, reflecting the continuing necessity for advanced diagnostic tools in early disease detection and personalized medicine. Therapeutics emerges second at 28%, as the shift toward minimally invasive procedures and advanced implantable devices gains traction. Monitoring devices capture 16%, with patient demand for continuous health tracking on the rise. Surgery and research applications occupy 12% and 9% of the market respectively. This segmentation illustrates growing investment across the entire care continuum, from diagnosis to treatment and post-care monitoring.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-medical-device-technologies-market

Frequently Asked Questions

Who are the key players in North America Medical Device Technologies Market industry?
The top five players are Medtronic, Johnson & Johnson, GE Healthcare, Abbott Laboratories, and Stryker Corporation. These companies lead through advanced product development, extensive R&D investments, and broad portfolios in cardiology, diagnostics, surgery, and digital health technologies, securing strong market presence across North America.

What is the North America Medical Device Technologies Market growth?
The North America Medical Device Technologies Market is experiencing steady growth, driven by technological advancements and increasing chronic disease prevalence. For example, Abbott Laboratories reported significant revenue increases in its diagnostics segment, fueled by innovations in point-of-care testing and continuous glucose monitoring in 2023.

Which segment accounted for the largest North America Medical Device Technologies Market share?
The diagnostic imaging segment holds the largest market share, owing to the rising adoption of MRI, CT, and ultrasound systems in hospitals and clinics. Increasing investment in imaging solutions for early disease detection is fueling strong demand, especially from top healthcare providers using GE Healthcare and Siemens equipment.

Thanks & Regards,
Priya
sales@bussinessinsights.com